Búsqueda | SciELO

Abstract Background: There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods: This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann-Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19. Results: From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03-2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19-6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31-3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46-0.98). Conclusion: Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR - 9KTWX6).

https://doi.org/10.1186/s42358-021-00217-0 22 descargas

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Reis Neto, Edgard Torres dos

; Kakehasi, Adriana Maria

; Pinheiro, Marcelo de Medeiros

; Ferreira, Gilda Aparecida

; Marques, Cláudia Diniz Lopes

; Mota, Licia Maria Henrique da

; Paiva, Eduardo dos Santos

; Pileggi, Gecilmara Cristina Salviato

; Sato, Emília Inoue

; Reis, Ana Paula Monteiro Gomides

; Xavier, Ricardo Machado

; Provenza, José Roberto

Advances in Rheumatology

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

2020, Volumen 60 elocation 32

Resumen: En | Texto: En | PDF: En

Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.

https://doi.org/10.1186/s42358-020-00134-8 2393 descargas

Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Ribeiro, Sandra Lúcia Euzébio

; Pereira, Helena Lúcia Alves

; Boechat, Antonio Luiz

; Silva, Neusa Pereira

; Sato, Emilia Ionue

; Cunha, Maria das Graças Souza

; Passos, Luiz Fernando de Souza

; Dos-Santos, Maria Cristina

Advances in Rheumatology

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

2019, Volumen 59 elocation 52

Resumen: En | Texto: En | PDF: En

Abstract Introduction: Antiphospholipid antibodies (aPL) are described in individuals with leprosy without the clinical features of antiphospholipid antibody syndrome (APS), a condition involving thromboembolic phenomena. We have described the persistence of these antibodies for over 5 years in patients with leprosy after specific treatment. Objectives: To determine whether epidemiological, clinical and immunological factors played a role in the longterm persistence of aPL antibodies in leprosy patients after multidrug therapy (MDT) had finished. Methods: The study sample consisted of 38 patients with a diagnosis of leprosy being followed up at the Dermatology and Venereology Outpatient Department at the Alfredo da Matta Foundation (FUAM) in Manaus, AM. ELISA was used to detect anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. Patients were reassessed on average of 5 years after specific treatment for the disease (MDT) had been completed. Results: Persistence of aPL antibodies among the 38 leprosy patients was 84% (32/38), and all had the IgM isotype. Mean age was 48.1 ± 15.9 years, and 23 (72.0%) were male. The lepromatous form (LL) of leprosy was the most common (n = 16, 50%). Reactional episodes were observed in three patients (9.4%). Eighteen (47.37%) were still taking medication (prednisone and/or thalidomide). Mean IgM levels were 64 U/mL for aCL and 62 U/mL for anti-β2GPI. In the multivariate binary logistic regression the following variables showed a significant association: age (p = 0.045, OR = 0.91 and CI 95% 0.82-0.98), LL clinical presention (p = 0.034; OR = 0.02 and CI 95% = 0.0-0.76) and bacterial index (p = 0.044; OR = 2.74 and CI 95% = 1.03-7.33). We did not find association between prednisone or thalidomide doses and positivity for aPL (p = 0.504 and p = 0.670, respectively). No differences in the variables vascular thrombosis, pregnancy morbidity, diabetes, smoking and alcoholism were found between aPL-positive and aPL-negative patients. Conclusion: Persistence of positivity for aPL antibodies was influenced by age, clinical presentation and bacterial index. However, further studies are needed to elucidate the reason for this persistence, the role played by aPL antibodies in the disease and the B cell lineages responsible for generation of these antibodies.

https://doi.org/10.1186/s42358-019-0094-4 348 descargas

Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Conceição, Céu Tristão Martins

; Meinão, Ivone Minhoto

; Bombana, José Atilio

; Sato, Emília Inoue

Advances in Rheumatology

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

2019, Volumen 59 elocation 4

Resumen: En | Texto: En | PDF: En

Abstract Background: Systemic Lupus Erythematosus (SLE) is an autoimmune disease which impairs the quality of life. The objective of study was to evaluate the effectiveness of Brief Group Psychoanalytic Psychotherapy to improve quality of life, depression, anxiety and coping strategies in SLE patients. Methods: In a randomized clinical trial, 80 female SLE patients were allocated into two groups: therapy group (n = 37) and control group (n =43). Therapy group (TG) attended weekly psychotherapy sessions for 20 weeks; control group (CG) remained on a waiting list. Both groups received standard medical care. Questionnaires and scales were applied by blinded evaluators at baseline (T1) and after 20 weeks (T2): Socioeconomic Status, SLE International Collaborating Clinic/American College of Rheumatology-Damage Index, SLE International Disease Activity, SLE Specific Symptom Checklist, SLE Quality of life, Hospital Anxiety Depression Scale, Coping Strategies Inventory. Intent to treat intra- and inter-group analysis was performed for all variables in T1 and T2 using Qui-square, t-Student, Mann-Whitney and Wilcoxon tests. Analysis of Variance was used to compare categorical variables overtime. P < 0.05 was considered significant. Results: The mean age of patients was 42 years; 54% were white, with mean disease duration of years 12. At baseline, both groups were homogeneous in all variables, including medications. After 20 weeks of psychotherapy TG was significantly different from CG, with lower frequency of symptoms (p = 0.001), lower level of anxiety (p = 0.019) and depression (p = 0.022), better index in five of six domains of quality of life scale (p ≤ 0.005), including total SLEQOL (p < 0.001) and with higher positive planful problem solving strategy (p = 0.017). No change in disease activity score was observed in both groups. Conclusions: Psychoanalytic psychotherapy was effective to improve many domains of quality of life and one positive coping skill and to reduce SLE symptoms, anxiety and depression levels. Brief group psychotherapy can be a useful tool to complement medical care in SLE patients. Trial registration: Number NCT01840709.

https://doi.org/10.1186/s42358-019-0047-y 721 descargas

Efecto de los antimaláricos sobre los diferentes dominios del índice de daño SLICC en pacientes de la cohorte GLADEL
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics

Pons-Estel, Guillermo J.

; Quintana, Rosana

; Wojdyla, Daniel

; Alarcón, Graciela S.

; Serrano, Rosa María

; Ugarte-Gil, Manuel

; Pimentel-Quiroz, Víctor

; Soriano, Enrique R.

; Catoggio, Luis J.

; Scolnik, Marina

; Sacnun, Mónica

; Saurit, Verónica

; Caeiro, Francisco

; Alvarellos, Alejandro

; Sarano, Judith

; García, Mercedes

; Onetti, Laura

; Drenkard, Cristina

; Berbotto, Guillermo

; Scherbarth, Hugo R.

; Sato, Emilia

; Bonfa, Eloisa

; Ferreira Borba, Eduardo

; Costallat, Lilian

; Xavier, Ricardo

; Tavares Brenol, Joao C.

; Da Silva, Nilzio A.

; Cavalcanti, Fernando

; Massardo, Loreto

; Jacobelli, Sergio

; Neira, Oscar

; Molina, José F

; Vásquez, Gloria

; Gómez-Puerta, José A.

; Alonso Gonzalez, Luis

; Iglesias Gamarra, Antonio

; Guibert-Toledano, Marlene

; Reyes, Gil A.

; Cardiel, Mario H.

; Pascual-Ramos, Virginia

; García de la Torre, Ignacio

; Barile, Leonor

; Silveira, Luis H.

; Amigo, Mary-Carmen

; Sauza del Pozo, María Josefina

; Acevedo-Vásquez, Eduardo M.

; Alfaro-Lozano, José

; Segami, María Inés

; Chacón-Díaz, Rosa

; Abadi, Isaac

; Esteva Spinetti, María H

; Pons-Estel, Bernardo A.

Revista argentina de reumatología

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Sep 2018, Volumen 29 Nº 3 Paginas 6 - 10

Resumen: En Es | Texto: En Es | PDF: En | PDF: Es

Objective: To assess the effects of antimalarials (AM) over the items of the SLICC Damage Index (SDI). Methods: Patients with recent (≤2 years) diagnosis of systemic lupus erythematosus (SLE) from the GLADEL cohort were studied. End-point: increase in items SDI since cohort entry. Independent variables (socio-demographic, clinical, laboratory and treatment) were included. The effect of AM as a time dependent variable on most frequent SDI items (adjusting for potential confounders) was examined with a multivariable Cox regression model. Results: Of the 1466 patients included in this analysis, 1049 (72%) received AM with a median exposure time of 30 months (Q1-Q3: 11-57). Damage occurred in 665 (45%) patients during a median follow-up time of 24 months (Q1-Q3: 8-55). There were 301 integument, 208 renal, 149 neuropsychiatric, 98 musculoskeletal, 88 cardiovascular and 230 others less frequently represented damages. After adjusting for potential confounders at any time during follow-up, a lower risk of renal damage (HR 0.652; 95% CI: 0.472-0.901) and borderline for neuropsychiatric damage (HR 0.701, 95% CI: 0.481-1.024) was found. Conclusion: In the GLADEL cohort, after adjustment for possible confounding factors, AM were independently associated with a reduced risk of renal damage accrual.

Objetivos: Estimar el efecto de los antimaláricos (AM) sobre los diferentes dominios del índice de daño SLICC (SDI). Métodos: Se estudiaron pacientes con diagnóstico clínico reciente (≤2 años) de lupus eritematoso sistémico (LES) de la cohorte GLADEL. Variable de estudio: aumento en los dominios del SDI desde el ingreso a la cohorte. Variables independientes: características sociodemográficas, clínicas, laboratorio y tratamientos. El efecto de los AM, como variable dependiente del tiempo, sobre los dominios más frecuentes del SDI (ajustado por factores de confusión) fue examinado con un modelo de regresión de Cox multivariado. Resultados: De 1466 pacientes estudiados, 1049 (72%) recibieron AM con un tiempo medio de exposición de 30 meses (Q1-Q3: 11-57) y 665 pacientes (45%) presentaron daño durante un seguimiento medio de 24 meses (Q1-Q3: 8-55); 301 eventos fueron cutáneos, 208 renales, 149 neuropsiquiátricos, 98 musculoesqueléticos, 88 cardiovasculares y 230 otros. Después de ajustar por factores de confusión, el uso de AM se asoció a un menor riesgo de daño renal (HR 0,652; IC 95%: 0,472-0,901) y en el límite de la significancia estadística (HR 0,701, IC 95%: 0,481-1,024) para el dominio neuropsiquiátrico. Conclusión: En GLADEL, el uso de AM se asoció independientemente a un menor riesgo de daño acumulado renal.

162 descargas

Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu's arteritis
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Machado, Luiz Samuel Gomes

; Oliveira, Ana Cecilia Diniz

; Semedo-Kuriki, Patricia

; Souza, Alexandre Wagner Silva de

; Sato, Emilia Inoue

Advances in Rheumatology

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

2018, Volumen 58 elocation 24

Resumen: En | Texto: En | PDF: En

Abstract Background: Endothelial progenitor cells (EPCs) are responsible for endothelial damage repair. Takayasu's arteritis (TA) is a chronic inflammatory disease that affects large vessels. The aim of the study was to evaluate the number of EPCs and the levels of vascular endothelial growth factor (VEGF) and the relationship of these variables in patients with TA. Methods: Thirty women with TA and 30 healthy controls were included. EPCs were assessed by flow cytometry and cell culture and VEGF quantification was performed by commercial ELISA kits. Results: Ages of patients and controls were similar. The number of EPCs in patients and controls (median (interquartile range) were 0.0073% (0.0081%) vs. 0.0062% (0.0089%), p = 0.779 by flow cytometry and 27.0 (42.3) colony forming units (CFUs) vs. 27.0 (20.5) CFUs, p = 0.473 by cells culture, respectively. VEGF levels in patients and controls was 274.5 (395.5) pg/ml vs. 243.5 (255.3) pg/ml, p = 0.460. There was no difference in the number of EPCs and VEGF level between patients with active and inactive disease. There was a tendency of the number of angioblast-like EPCs in patients taking anti-TNFs to be higher; and in patients using methotrexate to be lower. Conclusion: No significant difference was found in the quantification of EPCs and VEGF levels in TA patients compared to controls, and no difference was observed between patients with active and inactive disease.

https://doi.org/10.1186/s42358-018-0025-9 288 descargas

Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Faludi, André Arpad

; Izar, Maria Cristina de Oliveira

; Saraiva, José Francisco Kerr

; Chacra, Ana Paula Marte

; Bianco, Henrique Tria

; Afiune Neto, Abrahão

; Bertolami, Adriana

; Pereira, Alexandre C.

; Lottenberg, Ana Maria

; Sposito, Andrei C.

; Chagas, Antonio Carlos Palandri

; Casella Filho, Antonio

; Simão, Antônio Felipe

; Alencar Filho, Aristóteles Comte de

; Caramelli, Bruno

; Magalhães, Carlos Costa

; Negrão, Carlos Eduardo

; Ferreira, Carlos Eduardo dos Santos

; Scherr, Carlos

; Feio, Claudine Maria Alves

; Kovacs, Cristiane

; Araújo, Daniel Branco de

; Magnoni, Daniel

; Calderaro, Daniela

; Gualandro, Danielle Menosi

; Mello Junior, Edgard Pessoa de

; Alexandre, Elizabeth Regina Giunco

; Sato, Emília Inoue

; Moriguchi, Emilio Hideyuki

; Rached, Fabiana Hanna

; Santos, Fábio César dos

; Cesena, Fernando Henpin Yue

; Fonseca, Francisco Antonio Helfenstein

; Fonseca, Henrique Andrade Rodrigues da

; Xavier, Hermes Toros

; Mota, Isabela Cardoso Pimentel

; Giuliano, Isabela de Carlos Back

; Issa, Jaqueline Scholz

; Diament, Jayme

; Pesquero, João Bosco

; Santos, José Ernesto dos

; Faria Neto, José Rocha

; Melo Filho, José Xavier de

; Kato, Juliana Tieko

; Torres, Kerginaldo Paulo

; Bertolami, Marcelo Chiara

; Assad, Marcelo Heitor Vieira

; Miname, Márcio Hiroshi

; Scartezini, Marileia

; Forti, Neusa Assumpta

; Coelho, Otávio Rizzi

; Maranhão, Raul Cavalcante

; Santos Filho, Raul Dias dos

; Alves, Renato Jorge

; Cassani, Roberta Lara

; Betti, Roberto Tadeu Barcellos

; Carvalho, Tales de

; Martinez, Tânia Leme da Rocha

; Giraldez, Viviane Zorzanelli Rocha

; Salgado Filho, Wilson

Arquivos Brasileiros de Cardiologia

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Ago 2017, Volumen 109 Nº 2 Paginas 1 - 76

Resumen: Pt | Texto: Pt | PDF: Pt

https://doi.org/10.5935/abc.20170121 199102 descargas

18F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu's arteritis
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Arraes, Anne E.D.

; Souza, Alexandre W.S. de

; Mariz, Henrique A.

; Silva, Neusa P.

; Torres, Ivone C.G.

; Pinto, Paula N.V.

; Lima, Eduardo N.P.

; Sato, Emilia I.

Revista Brasileira de Reumatologia

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Ago 2016, Volumen 56 Nº 4 Paginas 299 - 308

Resumen: Pt En | Texto: Pt En | PDF: Pt | PDF: En

RESUMO Objetivo: Avaliar a captação de 18F-fluordesoxiglicose (FDG) na tomografia por emissão de pósitrons – tomografia computadorizada (PET-CT) – e os níveis séricos de diferentes citocinas e da metaloproteinases da matriz (MMP) em pacientes com arterite de Takayasu (AT) e associações com a atividade da doença. Métodos: Foram mensurados os níveis séricos do fator de necrose tumoral-α (TNF-α), interleucina (IL)-2, IL-6, IL-8, IL-12, IL-18, MMP-3 e MMP-9 em 36 pacientes com AT e 36 controles. O valor padronizado de captação máximo (SUVmax) de 18F-FDG nas paredes arteriais foi determinado por exames de PET-CT. Os pacientes com AT foram classificados como doença ativa, doença inativa e possível doença ativa. Resultados: Os níveis séricos de IL-6 e MMP-3 foram mais altos em pacientes com AT do que nos controles (p < 0,001). Os níveis séricos de IL-6 foram mais elevados em pacientes com doença ativa e em pacientes com possível doença ativa do que naqueles com doença inativa (p < 0,0001). Os pacientes com doença ativa apresentaram níveis séricos mais elevados de TNF-α do que os pacientes com doença inativa (p = 0,049), enquanto os indivíduos com possível doença ativa apresentaram maiores níveis séricos de IL-18 do que os pacientes com doença inativa (p = 0,046). Aqueles com doença ativa apresentaram maiores valores de SUVmax do que aqueles com doença inativa (p = 0,042). De acordo com a curva ROC, o SUVmax foi capaz de predizer a doença ativa na AT e valores ≥ 1,3 estavam associados à atividade da doença (p = 0,039). Os níveis séricos de TNF-α foram maiores em pacientes com SUVmax ≥ 1,3 do que naqueles com valor < 1,3 (p = 0,045) e controles (p = 0,012). Os níveis séricos de IL-6 foram mais elevados em pacientes com SUVmax ≥ 1,3 do que nos controles (p < 0,001). Não foram encontradas diferenças em relação a outros biomarcadores entre pacientes com AT e controles. Conclusões: Níveis séricos elevados de IL-6 e TNF-α, bem como uma maior captação arterial de 18F-FDG, estão associados à AT ativa.

ABSTRACT Objective: To evaluate 18F-fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography–computed tomography (PET–CT) and serum levels of different cytokines and matrix metalloproteinases (MMPs) in patients with Takayasu arteritis (TA) and associations with disease activity. Methods: Serum levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-2, IL-6, IL-8, IL-12, IL-18, MMP-3 and MMP-9 were measured in 36 TA patients and 36 controls. Maximum standard uptake value (SUVmax) of 18F-FDG in arterial walls was determined by PET–CT scans. TA patients were classified as active disease, inactive disease and possible active disease. Results: Serum IL-6 and MMP-3 levels were higher in TA patients than in controls (p < 0.001). Serum IL-6 was higher in patients with active disease and in patients with possible active disease than in inactive disease (p < 0.0001). Patients with active disease had higher serum TNFα levels than patients with inactive disease (p = 0.049) while patients with possible active disease presented higher IL-18 levels than patients with inactive disease (p = 0.046). Patients with active disease had higher SUVmax values than those with inactive disease (p = 0.042). By receiver operating characteristic (ROC) curve SUVmax was predictive of active disease in TA and values ≥1.3 were associated with disease activity (p = 0.039). Serum TNF-α levels were higher in patients with SUVmax ≥ 1.3 than <1.3 (p = 0.045) and controls (p = 0.012). Serum IL-6 levels were higher in patients with SUVmax ≥ 1.3 than in controls (p < 0.001). No differences regarding other biomarkers were found between TA patients and controls. Conclusions: Higher serum IL-6 and TNFα levels as well as higher 18F-FDG uptake in arterial wall are associated with active TA.

https://doi.org/10.1016/j.rbre.2015.08.007 3027 descargas

Leflunomide in Takayasu arteritis – A long term observational study
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Souza, Alexandre Wagner Silva de

; Agustinelli, Renan de Almeida

; Almeida, Hemerli de Cinque

; Oliveira, Patrícia Bermudes

; Pinheiro, Frederico Augusto Gurgel

; Oliveira, Ana Cecilia Diniz

; Sato, Emilia Inoue

Revista Brasileira de Reumatologia

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Ago 2016, Volumen 56 Nº 4 Paginas 371 - 375

Resumen: Pt En | Texto: Pt En | PDF: Pt | PDF: En

RESUMO Objetivo: Avaliar os dados de seguimento em longo prazo em relação à eficácia e toxicidade do tratamento com leflunomida em pacientes com arterite de Takayasu (AT) previamente recrutados no estudo aberto original dos efeitos de curto prazo da leflunomida na AT. Métodos: Fez-se um estudo longitudinal aberto de longo prazo com pacientes que preencheram os critérios para AT da American College of Rheumatology de 1990 e que participaram de um estudo anterior que avaliou a eficácia em curto prazo da leflunomida na AT. Obtiveram-se informações completas do seguimento de 12 dos 15 pacientes incluídos no estudo original. A atividade da doença foi avaliada pelos critérios de Kerr e pelo Indian Takayasu Activity Score 2010 (ITAS2010). Resultados: O tempo médio de seguimento foi de 43,0 ± 7,6 meses. Cinco (41,6%) pacientes com AT permaneceram em tratamento com leflunomida, enquanto sete (58,3%) tiveram de mudar para outro tratamento em razão da falha em prevenir recidivas em seis pacientes e toxicidade em um paciente. Não foram encontradas diferenças significativas entre os pacientes que continuaram o tratamento com leflunomida e aqueles que mudaram para outro agente em relação à idade no início do estudo, tempo desde o diagnóstico, dose diária de prednisona no início do estudo, ITAS2010 inicial, valor médio ou máximo de VHS e PCR, e dose de prednisona cumulativa no fim do estudo. Entre os dois pacientes com AT que mudaram de leflunomida para outro agente, dois tiveram uma recidiva clínica e precisaram mudar de tratamento. Conclusão: A leflunomida levou à remissão sustentada em aproximadamente metade dos pacientes por um período médio de 12 meses e foi bem tolerada pelos pacientes com AT.

ABSTRACT Objective: To evaluate the extended follow-up data on efficacy and toxicity of leflunomide therapy in Takayasu arteritis (TA) patients previously enrolled in the original open-label study of short-term effects of leflunomide in TA. Methods: An open-label long-term longitudinal study was performed in TA patients who fulfilled the 1990 American College of Rheumatology criteria for TA and had participated in a previous study that evaluated short-term efficacy of leflunomide in TA. Complete follow-up information could be retrieved from 12 out of 15 patients enrolled in the original study. Disease activity was evaluated by Kerr's criteria and by the Indian Takayasu Activity Score 2010 (ITAS2010). Results: The mean follow up time was 43.0 ± 7.6 months and 5 (41.6%) TA patients remained on leflunomide therapy while 7 (58.3%) TA patients had to change to another therapy due to failure to prevent relapses in 6 patients and toxicity in one patient. No significant differences were found between patients who remained on leflunomide therapy and those who changed to another agent regarding age at study entry, time since diagnosis, prednisone daily dose at study entry, baseline ITAS2010, mean or maximum ESR and CRP, and cumulative prednisone dose at study end. Among TA patients who had changed leflunomide to another agent, two had an additional clinical relapse and needed to change therapy. Conclusion: Leflunomide led to sustained remission in approximately half of patients at a mean time of 12 months and was well tolerated by TA patients.

https://doi.org/10.1016/j.rbre.2016.02.003 1412 descargas

10.

Visual loss resulting from immunosuppressive therapy in patients with syphilitic uveitis
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Afonso, Vivian Cristina Costa

; Nascimento, Heloisa

; Belfort, Rubens M.

; Sato, Emilia Inoue

; Muccioli, Cristina

; Belfort Jr., Rubens

Arquivos Brasileiros de Oftalmologia

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Jun 2015, Volumen 78 Nº 3 Paginas 185 - 186

Resumen: Pt En | Texto: Pt En | PDF: Pt | PDF: En

RESUMO Elucidar os efeitos adversos do uso de medicações imunossupressoras em pacientes com uveíte não diagnosticada por sífilis. Avaliação de quatro pacientes com uveíte por sífilis submetidos a tratamento com drogas imunossupressoras por suspeita de uveíte secundária a doenças reumáticas, que desenvolveram perda visual permanente. Sífilis deve ser sempre um diagnóstico diferencial nas doenças inflamatórias oculares, principalmente antes do início de terapia imunossupressora.

ABSTRACT Permanent visual loss can be caused by improper use of immunosuppressive therapy in cases of uveitis without differential diagnosis of syphilitic uveitis. We present four cases of syphilitic uveitis that were incorrectly diagnosed as being secondary to rheumatic diseases and were subsequently treated with immunosuppressive therapy, leading to permanent visual loss. These cases highlight the importance of ruling out syphilis in the differential diagnosis of inflammatory ocular diseases before starting use of immunosuppressive therapy.

https://doi.org/10.5935/0004-2749.20150047 2408 descargas

11.

Consenso da Sociedade Brasileira de Reumatologia para o diagnóstico, manejo e tratamento da nefrite lúpica
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Klumb, Evandro Mendes

; Silva, Clovis Artur Almeida

; Lanna, Cristina Costa Duarte

; Sato, Emilia Inoue

; Borba, Eduardo Ferreira

; Brenol, João Carlos Tavares

; Albuquerque, Elisa Martins das Neves de

; Monticielo, Odirlei Andre

; Costallat, Lilian Tereza Lavras

; Latorre, Luiz Carlos

; Sauma, Maria de Fátima Lobato da Cunha

; Bonfá, Eloisa Silva Dutra de Oliveira

; Ribeiro, Francinne Machado

Revista Brasileira de Reumatologia

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Feb 2015, Volumen 55 Nº 1 Paginas 1 - 21

Resumen: Pt En | Texto: Pt En | PDF: Pt | PDF: En

Objetivo Elaborar recomendações para o diagnóstico, manejo e tratamento da nefrite lúpica no Brasil. Método Revisão extensa da literatura com seleção dos artigos com base na força de evidência científica e opinião dos membros da Comissão de Lúpus Eritematoso Sistêmico da Sociedade Brasileira de Reumatologia. Resultados e conclusões 1) A biópsia renal deve ser feita sempre que possível e houver indicação e quando não for possível, o tratamento deve ser orientado com base na inferência da clase histológica. 2) Devem ser implementados medidas e cuidados idealmente antes do início do tratamento, com ênfase na atenção ao risco de infecção. 3) Devem-se compartilhar riscos e benefícios do tratamento com pacientes e familiares. 4) O uso da hidroxicloroquina (preferencialmente) ou difosfato de cloroquina é recomendado para todos os pacientes (exceto contraindicação) durante as fases de indução e manutenção. 5) A avaliação da eficácia do tratamento deve ser feita com critérios objetivos de resposta (remissão completa/remissão parcial/refratariedade). 6) Os IECA e/ou BRA são recomendados como antiproteinúricos para todos os pacientes (exceto contraindicação). 7) A identificação de sinais clínicos e/ou laboratoriais sugestivos de GN laboratoriais sugestivos de glomerulonefrite proliferativa ou membranosa deve indicar início imediato de terapia específica incluindo corticosteroides e agente imunossupressor, mesmo que não seja possível comprovação histológica. 8) O tempo de uso dos imunossupressores deve ser no mínimo de 36 meses, mas eles podem ser mantidos por períodos mais longos. A sua suspensão só deve ser feita quando o paciente atingir e mantiver remissão completa sustentada. 9) Deve-se considerar nefrite lúpica refratária quando a remissão completa ou parcial não for alcançada após 12 meses de tratamento adequado, quando uma nova biópsia renal deve ser considerada para auxiliar na identificação da causa da refratariedade e decisão terapêutica.

Objective To develop recommendations for the diagnosis, management and treatment of lupus nephritis in Brazil. Method Extensive literature review with a selection of papers based on the strength of scientific evidence and opinion of the Commission on Systemic Lupus Erythematosus members, Brazilian Society of Rheumatology. Results and conclusions (1) Renal biopsy should be performed whenever possible and if this procedure is indicated; and, when the procedure is not possible, the treatment should be guided with the inference of histologic class. (2) Ideally, measures and precautions should be implemented before starting treatment, with emphasis on attention to the risk of infection. (3) Risks and benefits of treatment should be shared with the patient and his/her family. (4) The use of hydroxychloroquine (preferably) or chloroquine diphosphate is recommended for all patients (unless contraindicated) during induction and maintenance phases. (5) The evaluation of the effectiveness of treatment should be made with objective criteria of response (complete remission/partial remission/refractoriness). (6) Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers are recommended as antiproteinuric agents for all patients (unless contraindicated). (7) The identification of clinical and/or laboratory signs suggestive of proliferative or membranous glomerulonephritis should indicate an immediate implementation of specific therapy, including corticosteroids and an immunosuppressive agent, even though histological confirmation is not possible. (8) Immunosuppressives must be used during at least 36 months, but these medications can be kept for longer periods. Its discontinuation should only be done when the patient could achieve and maintain a sustained and complete remission. (9) Lupus nephritis should be considered as refractory when a full or partial remission is not achieved after 12 months of an appropriate treatment, when a new renal biopsy should be considered to assist in identifying the cause of refractoriness and in the therapeutic decision.

https://doi.org/10.1016/j.rbr.2014.09.008 84295 descargas

12.

Surto de sarampo na região metropolitana de Campinas, SP
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Fernandes, Eder Gatti

; Oliveira, Maria Emília Braite de

; Fred, João

; Carelli, Luzia Auxiliadora

; Lima, Gisele Dias de Freitas

; Sato, Helena Keico

; Yu, Ana Lucia Frugis

Revista de Saúde Pública

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Dic 2013, Volumen 47 Nº 6 Paginas 1213 - 1217

Resumen: Pt En Es | Texto: Pt En Es | PDF: Pt | PDF: En | PDF: Es

O Brasil não apresenta circulação endêmica do vírus do sarampo desde o ano 2000. Entre maio e junho de 2011, a Região Metropolitana de Campinas, Estado de São Paulo, registrou três casos de sarampo. Foram descritos casos, as medidas de controle, a busca de possível fonte e de casos secundários. A caracterização genotípica do vírus identificou o genótipo D4, circulante no continente europeu. Não foram encontrados casos índice ou secundários. As medidas de controle efetuadas, aliadas à cobertura vacinal adequada da Região Metropolitana de Campinas contribuíram para que a transmissão da doença fosse interrompida.

Brazil has not had endemic circulation of the measles virus since 2000. Between May and June 2011, the Metropolitan Region of Campinas, State of Sao Paulo, Southeastern Brazil, reported three cases of measles. This report presents a descriptive study of the cases, control measures, and the search for a possible source and secondary cases. The genotypic characterization of the virus identified genotype D4, circulating in Europe. Secondary cases or index case were not found. The control measures and adequate vaccination coverage in Metropolitan Region of Campinas contributed to the interruption of disease transmission.

Brasil no presenta circulación endémica del virus sarampión desde el año 2000. Entre mayo y junio de 2011, la Región Metropolitana de Campinas, Estado de Sao Paulo, registró tres casos de sarampión. Se describieron los casos, las medidas de control, la búsqueda de la posible fuente y de casos secundarios. La caracterización genotípica del virus identificó el genotipo D4. No se encontraron casos índices o secundarios. Las medidas de control efectuadas, aliadas a la adecuada cobertura de la vacuna en la Región Metropolitana de Campinas contribuyeron para que la transmisión de la enfermedad fuera interrumpida.

https://doi.org/10.1590/S0034-8910.2013047004788 5387 descargas Citado 2 veces en SciELO

13.

Surto de sarampo na regiao metropolitana de Campinas, SP
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Fernandes, Eder Gatti

; Oliveira, Maria Emilia Braite de

; Fred, Joao

; Carelli, Luzia Auxiliadora

; Lima, Gisele Dias de Freitas

; Sato, Helena Keico

; Yu, Ana Lucia Frugis

Revista de Saúde Pública

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Dic 2013, Volumen 47 Nº 6 Paginas 1213 - 1217

Resumen: Pt En Es | Texto: Pt En Es | PDF: Pt | PDF: En | PDF: Es

https://doi.org/10.1590/S0034-8910.2013047004788 2099 descargas Citado 2 veces en SciELO

14.

Anticorpos antinucleossomo e síndrome antifosfolipídica: estudo observacional
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics

Souza, Alexandre Wagner Silva de

; Keusseyan, Silene Peres

; Silva, Neusa Pereira da

; Sato, Emilia Inoue

; Andrade, Luis Eduardo Coelho

Revista Brasileira de Reumatologia

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

Jun 2012, Volumen 52 Nº 3 Paginas 361 - 365

Resumen: Pt En | Texto: Pt En | PDF: Pt | PDF: En

OBJETIVO: Avaliar a associação entre a presença de anticorpos antinucleossomo (anti-NCS) e a síndrome antifosfolipídica primária (SAFP) e o posterior desenvolvimento de lúpus eritematoso sistêmico (LES). MATERIAIS E MÉTODOS: Trinta e seis mulheres com o diagnóstico de SAFP foram avaliadas prospectivamente para manifestações de doenças reumáticas autoimunes e para a presença de anticorpos antifosfolípides, anticorpos antinucleares e anti-NCS/cromatina. RESULTADOS: Após um período médio de seguimento de 45,7 meses, anticorpos anti-NCS/cromatina foram detectados em apenas uma paciente (2,8%), que desenvolveu manifestações de LES tais como poliartrite, linfopenia, neurite óptica, lesões compatíveis com esclerose múltipla em substância branca cerebral e perfil de autoanticorpos altamente sugestivo de LES. CONCLUSÃO: A frequência de anticorpos anti-NCS/cromatina é baixa em pacientes com SAFP, e sua presença pode associar-se ao desenvolvimento de manifestações de LES.

OBJECTIVE: To study the association of anti-nucleosome (anti-NCS) antibodies in primary antiphospholipid syndrome (APS) and the development of systemic lupus erythematosus (SLE) during follow-up. MATERIALS AND METHODS: Thirty-six women with primary APS were evaluated prospectively for clinical features of systemic autoimmune diseases and for the presence of antiphospholipid antibodies, antinuclear antibodies and anti-NCS/chromatin antibodies. RESULTS: After a mean follow-up period of 45.7 months, anti-NCS/chromatin antibodies were detected in only one patient (2.8%), who developed features of SLE including polyarthritis, lymphopenia, optic neuritis, multiple sclerosis-like lesions, and an autoantibody profile suggestive of SLE. CONCLUSION: The frequency of anti-NCS/chromatin antibodies in primary APS patients is very low, and they may be associated with the development of SLE manifestations.

5269 descargas

15.

IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions
Facebook Twitter

Otras redes sociales
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Otras redes

Métrica
- SciELO Analytics

Carneiro, José Ronaldo M

; Fuzii, Hellen T

; Kayser, Cristiane

; Alberto, Fernando L

; Soares, Fernando A

; Sato, Emília I

; Andrade, Luís Eduardo C

Clinics

Métricas del periódico
- Sobre o periódico
- SciELO Analytics

2011, Volumen 66 Nº 1 Paginas 77 - 82

Resumen: En | Texto: En | PDF: En

OBJECTIVE: To analyze cytokine gene expression in keratinocytes from patients with systemic lupus erythematosus (SLE). INTRODUCTION: Keratinocytes represent 95% of epidermal cells and can secrete several cytokines. METHODS: Keratinocytes were obtained by laser microdissection from 21 patients with SLE (10 discoid and 11 acute lesions) at involved and uninvolved sites. All patients were receiving a low/moderate prednisone dose and 18 were receiving chloroquine diphosphate. IL-2, IL-5, TNF-α and IFN-γ gene expression was evaluated by real-time PCR and expressed as the ratio (R) to a pool of skin samples from 12 healthy volunteers. RESULTS: Heterogeneity in cytokine gene expression was found among patients with SLE. Eighteen of 38 valid SLE samples (47%) presented overexpression (R>1) of at least one cytokine. Lesional skin samples tended to show higher cytokine expression than samples from uninvolved skin (p = 0.06). IL-5 and IFN-γ were the most commonly overexpressed cytokines. Samples with cytokine overexpression corresponded to more extensive and severe lesions. Prednisone dose did not differ between samples without cytokine overexpression (15.71±3.45 mg/day) and those with overexpressed cytokines (12.68±5.41 mg/day) (p = 0.216). Samples from all patients not receiving diphosphate chloroquine had at least one overexpressed cytokine. CONCLUSIONS: The heterogeneous keratinocyte cytokine gene expression reflects the complex immunological and inflammatory background in SLE. Patients with severe/extensive skin lesions showed a higher frequency of cytokine gene overexpression. Increased IFN-γ and IL-5 expression suggests that Th1 and Th2 cells are involved in SLE skin inflammation. The possibility that prednisone and antimalarial drugs may have contributed to low cytokine gene expression in some samples cannot be ruled out.

2704 descargas

Mostrar

itens por página

Página de 2 Próxima

Seleccione uno o más resultados

Todos Ordem alfabética

Resultados

Gráfico comparativo Descargar CSV

Visualizar estadísticas de

Enviar resultado

E-mail do(s) destinatário(s)*

Utilize ; (punto y coma) para más de un correo.

Enviar por correo-e

Esta página

Registros seleccionados

Todas las referencias (max. 300)

Su email

Asunto

Comentarios

Formato de exportación:

RIS (para EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citación

CSV (para Excel, etc)

Exportar:

Esta página

Itens seleccionados

Todas las referencias (max. 2000)

Sem resultados

No se encontraron documentos para su búsqueda

Glosario y ayuda para la búsqueda

Ud. puede enriquecer su búsqueda de una forma muy sencilla. Use los índices de búsqueda combinados con los conectores (AND u OR) para especificar su busca.

Por ejemplo, si desea buscar artículos acerca de
casos de dengue en el Brasil en 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

A continuación se muestra la lista completa de los índices de búsqueda que se pueden utilizar:

Cód. del Índice	Elemento
ti	título del articulo
au	autor
kw	palabras clave del artículo
subject	asunto (palabras del título, resumen y palabras clave)
ab	resumen
ta	título abreviado de la revista (ej. Cad. Saúde Pública)
journal_title	título completo de la revista (ej. Cadernos de Saúde Pública)
la	código de idioma de publicación (ej. pt - Portugués, es - Español)
type	tipo de documento
pid	identificador de la publicación
publication_year	año de publicación del artículo
sponsor	financiador
aff_country	código del país de la afiliación del autor
aff_institution	institución de filiación del autor
volume	volumen del artículo
issue	número del artículo
elocation	elocation
doi	número DOI
issn	ISSN de la revista
in	código de la colección SciELO (ej. scl - Brasil, col - Colômbia)
use_license	código de licencia de uso del artículo

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

Todo el contenido de este sitio www.scielo.br, excepto dónde está identificado, está bajo una Licencia de Atribución Creative Commons.
sepa más »